Nektar Therapeutics (NASDAQ:NKTR) Releases Earnings Results, Beats Expectations By $0.03 EPS

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03, Zacks reports. Nektar Therapeutics had a negative return on equity of 101.41% and a negative net margin of 195.02%. The business had revenue of $21.64 million during the quarter, compared to the consensus estimate of $14.91 million. During the same quarter in the previous year, the firm earned ($0.25) earnings per share.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR traded up $0.16 on Friday, reaching $1.76. The company's stock had a trading volume of 2,360,209 shares, compared to its average volume of 1,997,249. Nektar Therapeutics has a 52-week low of $0.41 and a 52-week high of $1.87. The company has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $0.78. The company has a market cap of $323.17 million, a P/E ratio of -1.91 and a beta of 0.71.

Analyst Ratings Changes

Several research firms recently weighed in on NKTR. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a report on Tuesday, March 5th. StockNews.com started coverage on shares of Nektar Therapeutics in a report on Friday, January 26th. They issued a "hold" rating for the company. Finally, Jefferies Financial Group upped their price target on Nektar Therapeutics from $0.50 to $1.00 and gave the company a "hold" rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $3.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.